Antony, Jayesh
Saikia, Minakshi
V, Vinod.
Nath, Lekshmi. R.
Katiki, Mohana Rao
Murty, M.S.R.
Paul, Anju
A, Shabna
Chandran, Harsha
Joseph, Sophia Margaret
S, Nishanth Kumar.
Panakkal, Elizabeth Jayex
V, Sriramya I.
V, Sridivya I.
Ran, Sophia
S, Sankar
Rajan, Easwary
Anto, Ruby John
Article History
Received: 11 January 2015
Accepted: 8 May 2015
First Online: 10 June 2015
Change Date: 3 August 2015
Change Type: Update
Change Details: A correction has been published and is appended to both the HTML and PDF versions of this paper. The error has not been fixed in the paper.
Change Date: 3 August 2015
Change Type: Erratum
Change Details: <i>Wrightia tinctoria</i> is a constituent of several ayurvedic preparations against skin disorders including psoriasis and herpes, though not yet has been explored for anticancer potential. Herein, for the first time, we report the significant anticancer properties of a semi-purified fraction, DW-F5, from the dichloromethane extract of <i>W. tinctoria</i> leaves against malignant melanoma. DW-F5 exhibited anti-melanoma activities, preventing metastasis and angiogenesis in NOD-SCID mice, while being non-toxic <i>in vivo</i>. The major pathways in melanoma signaling mediated through BRAF, WNT/β-catenin and Akt-NF-κB converging in MITF-M, the master regulator of melanomagenesis, were inhibited by DW-F5, leading to complete abolition of MITF-M. Purification of DW-F5 led to the isolation of two cytotoxic components, one being tryptanthrin and the other being an unidentified aliphatic fraction. The overall study predicts <i>Wrightia tinctoria</i> as a candidate plant to be further explored for anticancer properties and DW-F5 as a forthcoming drug formulation to be evaluated as a chemotherapeutic agent against malignant melanoma.
Competing interests
: The authors declare no competing financial interests.